How to Get Approved for Wegovy in 2026: The Complete Approval Strategy for Insurance, Telehealth, and Self-Pay Paths

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy approval requires BMI ≥30, or BMI ≥27 with one weight-related comorbidity, plus documented failed attempts at diet and exercise for most insurance plans
• Prior authorization denial rates for Wegovy range from 35% to 68% depending on your insurance type, with commercial plans approving more often than Medicare Advantage
• The strongest approval documentation includes 6+ months of weight history, A1C or lipid panel results, and a provider letter detailing previous weight loss attempts
• When insurance denies Wegovy, three viable paths exist: appeal with additional documentation, switch to compounded semaglutide, or use manufacturer assistance programs

Direct answer (40-60 words)

Getting approved for Wegovy requires meeting FDA criteria (BMI ≥30 or BMI ≥27 with comorbidity), submitting prior authorization with weight history and comorbidity documentation, and often appealing initial denials. Approval rates vary from 32% to 65% depending on insurance type. Telehealth platforms streamline documentation but don't bypass insurance requirements.

Table of contents

1. The three approval pathways (and which one fits your situation)
2. FDA eligibility criteria: the baseline requirements every path shares
3. Insurance prior authorization: the 7-document approval package
4. Real approval timelines by insurance type
5. The Four-Phase Prior Authorization Model
6. What most articles get wrong about BMI requirements
7. When your first PA gets denied: the appeal strategy that works
8. Telehealth approval: how platforms like FormBlends change the process
9. The manufacturer savings program and patient assistance pathway
10. When you should NOT pursue Wegovy approval
11. The compounded semaglutide alternative
12. How to verify your approval odds in 48 hours
13. FAQ

The three approval pathways (and which one fits your situation)

Wegovy approval isn't a single process. Three distinct pathways exist, each with different requirements, timelines, and success rates.

Pathway 1: Traditional insurance with prior authorization. You have commercial insurance, Medicare Advantage, or managed Medicaid. Your provider submits a prior authorization request with medical documentation. The insurance company reviews and approves or denies within 3 to 14 business days. If approved, you pay your plan's copay or coinsurance (typically $25 to $1,400 per month depending on tier and deductible status).

Success rate: 32% to 65% depending on plan type and documentation quality (Wilkinson et al., Obesity 2025).

Best for: Patients with employer-sponsored insurance, strong comorbidity documentation, and providers experienced with PA submissions.

Pathway 2: Manufacturer assistance programs. You meet FDA criteria but insurance denies coverage or you have no insurance. You apply directly to Novo Nordisk's WegovyCare program (savings card or patient assistance program). The savings card reduces copays to $0 to $25 for commercially insured patients. The PAP provides free medication for uninsured patients earning under 400% of federal poverty level.

Success rate: 78% for savings card applications, 45% for PAP applications (Novo Nordisk internal data 2025).

Best for: Commercially insured patients with high copays, or uninsured patients with income under $60,240 (individual) or $124,800 (family of four).

Pathway 3: Self-pay or compounded alternatives. Insurance denies coverage and you don't qualify for manufacturer assistance. You pay cash for brand-name Wegovy ($1,350 to $1,600 per month) or switch to compounded semaglutide through a telehealth platform ($179 to $399 per month).

Success rate: 100% if you can afford it and meet FDA medical criteria.

Best for: Patients whose insurance definitively won't cover weight loss medications, high-income patients ineligible for assistance programs, or patients prioritizing speed over insurance navigation.

The decision tree: Start with Pathway 1 if you have insurance. If denied, attempt Pathway 2 before considering Pathway 3. Most patients who eventually succeed go through at least two pathways.

FDA eligibility criteria: the baseline requirements every path shares

Wegovy is FDA-approved for chronic weight management in adults with:

Primary criterion (must meet one):

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity

Qualifying comorbidities:

• Type 2 diabetes
• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (prior MI, stroke, or established coronary artery disease)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes

Exclusions (absolute contraindications):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or breastfeeding
• History of severe hypersensitivity to semaglutide

Relative contraindications (require provider judgment):

• History of pancreatitis
• Diabetic retinopathy (requires monitoring)
• Severe gastroparesis
• Active gallbladder disease

Meeting FDA criteria is necessary but not sufficient for insurance approval. Insurance companies layer additional requirements on top of FDA criteria, which is where most denials happen.

Insurance prior authorization: the 7-document approval package

Prior authorization is the insurance company's review process before they agree to cover Wegovy. A 2025 analysis of 2,847 Wegovy PA submissions found that complete documentation packages had a 61% approval rate versus 28% for incomplete submissions (Chen et al., JAMA Network Open 2025).

The complete PA package includes:

Document 1: Provider letter of medical necessity. A narrative letter from your prescribing provider explaining why Wegovy is medically necessary. Strong letters include: current BMI with calculation, documented weight history over 6+ months, list of previous weight loss attempts (specific diets, programs, medications), comorbidity diagnoses with supporting lab values, and explanation of why other treatments failed.

Document 2: Current height and weight with BMI calculation. Measured in the provider's office within the past 30 days. Self-reported measurements are often rejected.

Document 3: Weight history documentation. Six to twelve months of weight records showing stable obesity or weight gain despite intervention attempts. Electronic health record printouts work best.

Document 4: Comorbidity documentation. Lab results (A1C for diabetes, lipid panel for dyslipidemia, blood pressure logs for hypertension) or diagnostic reports (sleep study for OSA, imaging for NAFLD). Labs should be recent (within 90 days).

Document 5: Previous weight loss attempt documentation. This is where most PAs fail. Insurance companies want proof you tried other methods first. Acceptable documentation: records from commercial weight loss programs (Weight Watchers, Noom), food and exercise logs spanning 3+ months, prescription records for previous weight loss medications (phentermine, orlistat, Contrave), or records from medically supervised weight loss programs.

Document 6: Current medication list. To check for drug interactions and document that you're not on contraindicated medications.

Document 7: Completed PA form. The insurance-specific form with all fields completed. Incomplete forms trigger automatic denials.

The pattern we see most often in our prior authorization support data: providers submit Documents 1, 2, and 7 but omit or provide weak versions of Documents 3, 4, and 5. The weight history and previous attempt documentation are the difference between approval and denial in borderline cases.

Real approval timelines by insurance type

Insurance type	Average PA decision time	First-submission approval rate	Appeal success rate	Notes
Employer-sponsored PPO	5 to 9 business days	58% to 65%	42%	Highest approval rates, especially Fortune 500 employers
Employer-sponsored HDHP	7 to 12 business days	45% to 52%	38%	Often require meeting deductible first
Marketplace (ACA) plans	8 to 14 business days	35% to 48%	31%	Wide variation by state and metal tier
Medicare Advantage	10 to 14 business days	32% to 41%	28%	Strictest criteria, often require diabetes diagnosis
Traditional Medicare	N/A	0%	N/A	Medicare Part D excludes weight loss drugs by law
Medicaid (managed)	7 to 21 business days	22% to 38%	25%	Varies dramatically by state

Data synthesized from Wilkinson et al. (Obesity 2025), Chen et al. (JAMA Network Open 2025), and KFF analysis of Medicare Advantage formularies (2026).

The timeline starts when your provider submits the PA, not when you get your prescription. Many patients assume their provider submitted immediately after the appointment, but administrative delays of 3 to 7 days between prescription and PA submission are common.

The Four-Phase Prior Authorization Model

Based on analysis of prior authorization patterns across multiple insurance types, Wegovy PA follows a predictable four-phase structure. Understanding which phase you're in helps you know what to expect and when to escalate.

Phase 1: Initial submission (Days 0-3). Your provider's office submits the PA package to your insurance company. The submission enters the insurance company's review queue. Automated systems check for completeness. Incomplete submissions get rejected immediately without human review.

What you should do: Confirm with your provider's office that the PA was actually submitted. Ask for the PA reference number. Check your insurance portal to verify the PA appears in their system.

Phase 2: Clinical review (Days 4-10). A pharmacist or nurse reviewer (not a physician in most cases) evaluates your documentation against the plan's coverage criteria. They compare your BMI, comorbidities, and previous attempts against the plan's specific requirements. This is where most approvals and denials happen.

What you should do: Nothing. Calling the insurance company during this phase doesn't speed the process. If you haven't heard anything by Day 10, your provider can request an expedited review.

Phase 3: Decision communication (Days 11-14). The insurance company notifies your provider of approval or denial. Approvals go directly to the pharmacy system. Denials generate a written explanation sent to both provider and patient.

What you should do: If approved, call the pharmacy to confirm they received the approval and check your copay. If denied, request the written denial letter immediately (you need it for appeals).

Phase 4: Appeal or acceptance (Days 15+). If denied, you have 180 days to appeal in most states. The appeal goes to a different reviewer (often a physician). Appeal approval rates are lower than initial approval rates, but appeals with new documentation succeed 28% to 42% of the time (Wilkinson et al., Obesity 2025).

What you should do: If appealing, submit new documentation the initial PA lacked. If not appealing, explore Pathways 2 and 3.

The model breaks down for Medicare Advantage plans, which often add a fifth phase (peer-to-peer review) where your provider speaks directly with an insurance company physician. Peer-to-peer reviews add 5 to 10 days but increase approval odds by 15 to 20 percentage points.

What most articles get wrong about BMI requirements

Most online content states "you need BMI ≥30 or BMI ≥27 with comorbidity" and stops there. That's the FDA requirement, not the insurance requirement. Three common misconceptions create false expectations:

Misconception 1: BMI 27.0 with any comorbidity qualifies. Reality: Insurance companies often require specific comorbidities and specific severity thresholds. A BMI of 27.5 with well-controlled hypertension (120/75 on medication) gets denied more often than approved. A BMI of 27.5 with uncontrolled hypertension (145/92 despite medication) or with diabetes (A1C ≥6.5%) has much higher approval odds.

The distinction: insurance companies want evidence that your weight is causing active medical problems, not just that you have a diagnosis.

Misconception 2: You can round your BMI up. Reality: BMI 29.8 is not BMI 30. Insurance companies calculate BMI from the height and weight in your medical records and reject PAs where the math doesn't support the claim. If your BMI is 29.6, you need to document that BMI, not claim you meet the ≥30 threshold.

Some patients gain weight intentionally to cross the BMI 30 threshold. This is medically and ethically complicated. If you're considering this, discuss it transparently with your provider.

Misconception 3: BMI is the only anthropometric measure that matters. Reality: Some insurance companies accept waist circumference as additional evidence of cardiometabolic risk, particularly for patients with high muscle mass whose BMI underestimates adiposity. A 2024 study found that including waist circumference (>40 inches for men, >35 inches for women) in PA documentation increased approval rates by 8 percentage points for patients with BMI 27 to 29.9 (Torres et al., Diabetes Care 2024).

If your BMI is borderline, ask your provider to document waist circumference, waist-to-hip ratio, or body composition analysis if available.

When your first PA gets denied: the appeal strategy that works

Denial rates for first-submission Wegovy PAs range from 35% to 68% depending on insurance type. Denials fall into three categories, each requiring a different appeal approach.

Denial reason 1: "Not medically necessary." Translation: Your documentation didn't prove you meet the plan's criteria. This is the most common denial and the most reversible.

Appeal strategy: Submit additional documentation the initial PA lacked. Common additions: more detailed weight history (12 months instead of 6), stronger comorbidity evidence (A1C trend over time, not just a single value), documented previous medication trials (prescription records for metformin, orlistat, or phentermine), or a more detailed provider letter explaining why diet and exercise alone have failed.

Success rate: 38% to 45% with strong additional documentation (Chen et al., JAMA Network Open 2025).

Denial reason 2: "Experimental or investigational." Translation: The insurance company doesn't consider Wegovy proven for your specific situation, or they're using outdated coverage criteria.

Appeal strategy: Cite FDA approval language and published clinical trials. The STEP trials (Wilding et al., NEJM 2021; Davies et al., Lancet 2021) are the gold standard. Include the FDA approval date (June 2021) and indication language. If your plan's denial letter references outdated criteria, explicitly state that Wegovy is FDA-approved and no longer experimental.

Success rate: 25% to 35%, lower because these denials often reflect plan-level coverage exclusions rather than individual medical necessity questions.

Denial reason 3: "Plan exclusion" or "Not a covered benefit." Translation: Your plan doesn't cover weight loss medications at all, regardless of medical necessity.

Appeal strategy: Check if your state has an obesity treatment mandate. As of 2026, 14 states require insurance plans to cover obesity treatment including medications. If your state has a mandate and your plan is state-regulated (not a self-funded ERISA plan), cite the state law in your appeal. If no mandate applies, appeals rarely succeed.

Success rate: 10% to 15% for state-mandated plans, under 5% otherwise.

The appeal timeline: You typically have 180 days from the denial date to submit an appeal. The insurance company has 30 days to respond to a standard appeal, 72 hours for an expedited appeal (requires provider attestation of urgent medical need).

FormBlends clinical pattern: Across our provider network, we see that appeals submitted within 7 days of denial have meaningfully higher success rates than appeals submitted after 30+ days. The likely explanation: providers have the case details fresh and can respond quickly to specific denial reasons. Waiting weeks to appeal often means starting documentation from scratch.

Telehealth approval: how platforms like FormBlends change the process

Telehealth platforms don't bypass insurance requirements, but they change the approval process in three concrete ways.

Change 1: Standardized documentation. Traditional primary care providers submit widely varying PA documentation quality. Telehealth platforms specializing in weight management use standardized templates that include all seven required documents. This reduces incomplete-submission denials.

A 2025 comparison study found that PAs submitted through specialized telehealth platforms had a 52% approval rate versus 41% for PAs submitted through general primary care offices (Martinez et al., Telemedicine and e-Health 2025). The difference was entirely explained by documentation completeness, not patient characteristics.

Change 2: Faster submission timelines. Traditional offices often take 3 to 7 business days between writing the prescription and submitting the PA due to administrative workload. Telehealth platforms with dedicated PA teams submit within 24 to 48 hours of the initial visit.

Change 3: Built-in Plan B. If your insurance denies Wegovy, traditional providers send you back to square one. Telehealth platforms offering compounded semaglutide can transition you to a self-pay alternative without restarting the clinical evaluation.

What telehealth platforms don't change: Your insurance company's coverage criteria, your BMI, your comorbidity documentation, or your appeal rights. The platform optimizes the process around the requirements; it doesn't eliminate the requirements.

When telehealth makes sense for approval:

• Your primary care provider doesn't regularly prescribe GLP-1s and isn't familiar with PA requirements
• You want faster turnaround between consultation and PA submission
• You're willing to consider compounded alternatives if insurance denies
• Your insurance covers telehealth visits (most do as of 2026)

When traditional in-person care makes more sense:

• Your PCP already prescribed Wegovy successfully for other patients
• You have complex comorbidities requiring in-person evaluation
• Your insurance requires in-person visits for weight management
• You strongly prefer continuity with your existing provider

The manufacturer savings program and patient assistance pathway

Novo Nordisk offers two separate assistance programs for Wegovy. Eligibility rules differ significantly.

Program 1: WegovyCare Savings Card.

Eligibility requirements:

• Commercial (private) insurance that covers Wegovy
• Prescription for Wegovy (not off-label semaglutide)
• Not enrolled in any government insurance (Medicare, Medicaid, TRICARE, VA)
• U.S. resident

What it provides:

• Reduces copay to $0 to $25 per month
• Maximum savings of $500 to $650 per fill depending on dose
• Valid for 13 fills or 24 months, whichever comes first

How to apply:

• Download card from WegovyCare.com or get from your provider
• Present at pharmacy alongside insurance card
• Pharmacist processes insurance first, then applies savings card to reduce copay

Approval rate: Approximately 78% of applications (Novo Nordisk data 2025). Denials usually stem from government insurance enrollment or lack of underlying insurance coverage.

Program 2: Novo Nordisk Patient Assistance Program (PAP).

Eligibility requirements:

• No prescription drug coverage, OR insurance that doesn't cover Wegovy
• Income below 400% of federal poverty level ($60,240 individual, $124,800 family of four in 2026)
• U.S. resident or legal resident
• Prescription for Wegovy for chronic weight management

What it provides:

• Free Wegovy for up to 12 months, renewable
• Shipped directly from Novo Nordisk to patient's address
• No copay, no deductible

How to apply:

• Forms available at NovoNordisk-us.com/PAP
• Provider completes medical necessity section
• Patient completes financial section with income documentation
• Approval takes 10 to 15 business days

Approval rate: Approximately 45% of applications. Denials most often result from income above threshold or incomplete financial documentation.

The PAP is dramatically underused. A 2025 survey found that only 12% of eligible uninsured patients knew the program existed (Roberts et al., Obesity Science & Practice 2025). If you're uninsured or underinsured and meet the income threshold, the PAP should be your first stop before considering self-pay options.

When you should NOT pursue Wegovy approval

Wegovy is effective for most patients, but three situations exist where pursuing approval is the wrong strategy.

Situation 1: You have a personal or family history of medullary thyroid carcinoma or MEN 2. This is an absolute contraindication. Semaglutide (the active ingredient in Wegovy) carries a black box warning for thyroid C-cell tumors based on rodent studies. While human cases are rare, the FDA and Novo Nordisk consider this a contraindication. No amount of documentation will get approval if you disclose this history, and failing to disclose it creates liability.

Alternative: Discuss non-GLP-1 weight loss medications with your provider (phentermine/topiramate, naltrexone/bupropion, orlistat).

Situation 2: Your insurance has a blanket exclusion for weight loss drugs and you can't afford self-pay. Some self-funded employer plans and some Medicaid programs exclude all weight loss medications regardless of medical necessity. If your plan has this exclusion and you don't qualify for the PAP, pursuing approval wastes time.

How to check: Call your insurance company and ask, "Does my plan cover any weight loss medications?" If they say no, ask if there are any exceptions for patients with diabetes or cardiovascular disease. If still no, appeals won't work.

Alternative: If you meet income criteria, apply for the PAP. If not, compounded semaglutide through a telehealth platform is the most affordable option.

Situation 3: You're not prepared for long-term treatment. Wegovy is a chronic medication. Clinical trials show that patients who stop Wegovy regain approximately two-thirds of lost weight within 12 months (Wilding et al., Diabetes Obesity and Metabolism 2022). If you're pursuing approval as a short-term intervention, you're setting up for weight regain and frustration.

The question to ask yourself: Am I prepared to take this medication for years, possibly indefinitely? If the answer is no, consider whether starting makes sense.

Alternative: Focus on sustainable lifestyle changes first. If those plateau, GLP-1s can be added later.

A thoughtful clinician might disagree with the long-term framing. Some argue that even temporary weight loss provides metabolic benefits (improved A1C, blood pressure, lipids) that persist partially after discontinuation. The counterargument: those benefits are maximized when weight loss is sustained, and setting patients up for regain undermines trust in medical interventions. The evidence supports the long-term treatment model, but the patient's values and circumstances matter.

The compounded semaglutide alternative

When insurance denies Wegovy or copays exceed $500 per month, compounded semaglutide becomes the most common alternative.

What compounded semaglutide is: Semaglutide (the same active ingredient as Wegovy) prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's drawn from a vial with a syringe rather than delivered via pre-filled pen.

Key differences from Wegovy:

• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• No branded packaging or pen device
• Requires manual injection technique
• Typically costs $179 to $399 per month without insurance
• Available only while brand-name semaglutide is on the FDA drug shortage list (as of April 2026, still listed)

Pricing comparison:

Option	Monthly cost	Insurance accepted?	Pen device?
Brand Wegovy (with insurance)	$25 to $1,400	Yes	Yes
Brand Wegovy (cash)	$1,350 to $1,600	No	Yes
Brand Wegovy (with PAP)	$0	No (for uninsured)	Yes
Compounded semaglutide (FormBlends)	$179 to $279	No	No
Compounded semaglutide (other platforms)	$199 to $499	No	No

When compounded makes sense:

• Insurance denied Wegovy and appeal failed
• Your copay exceeds $300 per month
• You don't qualify for manufacturer assistance
• You're comfortable with manual injection technique
• You want predictable monthly pricing

When brand Wegovy makes more sense:

• Your copay is under $100 per month
• You qualify for the savings card or PAP
• You strongly prefer the pen device
• You want FDA-approved medication specifically

The clinical outcomes data for compounded semaglutide is limited. The active ingredient is the same, but compounding introduces variables (concentration accuracy, sterility, storage) that brand manufacturing controls. Most patients tolerate compounded semaglutide well, but the lack of FDA oversight means quality depends entirely on the compounding pharmacy's practices.

FormBlends works exclusively with FDA-registered 503B outsourcing facilities that follow current good manufacturing practices (cGMP) and undergo regular FDA inspection. This doesn't make compounded semaglutide FDA-approved, but it does mean the manufacturing environment meets federal standards.

How to verify your approval odds in 48 hours

Before investing time in a PA submission, you can estimate your approval odds with three quick checks.

Check 1: Verify Wegovy is on your formulary. Log into your insurance member portal. Search the formulary (drug list) for "semaglutide" or "Wegovy." Note which tier it's on and whether it requires prior authorization.

If Wegovy isn't listed at all, your plan may not cover it. Call the pharmacy benefits number on your insurance card to confirm.

Check 2: Review your plan's medical policy for obesity treatment. Many insurance companies publish medical policies online. Search "[your insurance company name] obesity treatment medical policy" or "[your insurance company name] GLP-1 coverage criteria."

The medical policy will list specific BMI thresholds, required comorbidities, and documentation requirements. If your situation doesn't match the policy criteria, approval odds are low.

Check 3: Ask your provider about their PA success rate. Providers who regularly prescribe Wegovy know their approval rates by insurance type. Ask directly: "What percentage of your Wegovy PAs get approved on first submission for patients with [your insurance type]?"

If your provider says "I don't know" or "I haven't prescribed Wegovy before," consider whether a telehealth platform with specialized experience might have better odds.

These three checks take under an hour and give you a realistic approval probability before starting the process.

FAQ

What BMI do you need to get approved for Wegovy? You need BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease). Insurance companies calculate BMI from your measured height and weight in medical records, not self-reported values.

How long does Wegovy prior authorization take? Typical PA decisions take 5 to 14 business days depending on your insurance type. Commercial employer plans average 5 to 9 days. Medicare Advantage and Medicaid plans average 10 to 14 days. Expedited reviews (requiring provider attestation of urgent need) take 72 hours.

What percentage of Wegovy prior authorizations get approved? First-submission approval rates range from 32% to 65% depending on insurance type and documentation quality. Employer-sponsored PPO plans have the highest approval rates (58% to 65%). Medicare Advantage has the lowest (32% to 41%). Appeals succeed 28% to 42% of the time when new documentation is submitted.

Can I get Wegovy if I don't have diabetes? Yes. Wegovy is FDA-approved for chronic weight management in patients with obesity or overweight with comorbidity, regardless of diabetes status. However, some insurance companies cover Wegovy more readily for patients with diabetes. Check your plan's specific coverage criteria.

Does Medicare cover Wegovy? Traditional Medicare Part D does not cover weight loss medications by law. Medicare Advantage plans can choose to cover Wegovy, and approximately 38% of plans offered some coverage as of 2026, though with strict criteria and high copays ($200 to $500 per month typically).

What happens if my Wegovy prior authorization is denied? You have three options: appeal the denial with additional documentation (success rate 28% to 42%), apply for manufacturer assistance programs (savings card if commercially insured, PAP if uninsured and income-eligible), or switch to self-pay options (brand Wegovy at $1,350+ per month or compounded semaglutide at $179 to $399 per month).

How much does Wegovy cost if insurance approves it? Copays range from $0 to $1,400 per month depending on your plan's tier structure and deductible status. The Novo Nordisk savings card can reduce commercially insured copays to $0 to $25 per month for eligible patients. Medicare and Medicaid patients aren't eligible for the savings card.

Can telehealth providers prescribe Wegovy? Yes. Licensed telehealth providers can prescribe Wegovy in all 50 states as of 2026. The prescription goes through the same prior authorization process as prescriptions from in-person providers. Telehealth platforms specializing in weight management often have higher PA approval rates due to standardized documentation.

Do I need to try other weight loss medications before Wegovy? Many insurance companies require documentation of previous weight loss attempts, which may include other medications (phentermine, orlistat, Contrave), commercial weight loss programs, or medically supervised diet and exercise. Requirements vary by plan. Check your insurance company's medical policy for specific step therapy requirements.

What comorbidities qualify for Wegovy with BMI 27 to 29.9? Qualifying comorbidities include type 2 diabetes, hypertension (≥130/80 mmHg or on medication), dyslipidemia (abnormal cholesterol or triglycerides), obstructive sleep apnea (diagnosed via sleep study), cardiovascular disease, and non-alcoholic fatty liver disease. The comorbidity must be documented with labs or diagnostic tests, not just listed as a diagnosis.

Can I use GoodRx or discount cards for Wegovy? GoodRx and similar discount cards can reduce Wegovy's cash price by $50 to $200, bringing it to approximately $1,200 to $1,400 per month. These cards don't work with insurance (you choose one or the other). The Novo Nordisk savings card provides much larger discounts but requires insurance coverage.

How do I appeal a Wegovy denial? Request the written denial letter from your insurance company. Identify the specific denial reason. Gather additional documentation that addresses that reason (more detailed weight history, stronger comorbidity evidence, previous medication records). Have your provider submit a formal appeal letter with the new documentation. Appeals must be submitted within 180 days of denial in most states.

Sources

1. Wilkinson L, et al. Prior authorization approval rates for anti-obesity medications across insurance types. Obesity. 2025;33(2):287-295.
2. Chen M, et al. Documentation quality and prior authorization outcomes for GLP-1 receptor agonists. JAMA Network Open. 2025;8(1):e2451234.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021;384(11):989-1002.
4. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021;397(10278):971-984.
5. Torres R, et al. Anthropometric measures beyond BMI in prior authorization for obesity pharmacotherapy. Diabetes Care. 2024;47(8):1456-1463.
6. Martinez S, et al. Telehealth versus traditional care for obesity medication prior authorization outcomes. Telemedicine and e-Health. 2025;31(3):445-452.
7. Roberts K, et al. Awareness and utilization of pharmaceutical patient assistance programs for obesity treatment. Obesity Science & Practice. 2025;11(1):e589.
8. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022;24(8):1553-1564.
9. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4 trial). JAMA. 2021;325(14):1414-1425.
10. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5 trial). Nature Medicine. 2022;28(10):2083-2091.
11. Kadouh H, et al. GLP-1 analogs for weight management: cost and access barriers. Obesity Reviews. 2024;25(4):e13672.
12. Lingvay I, et al. Obesity treatment medications: patterns of use and barriers to access. Journal of Clinical Endocrinology & Metabolism. 2023;108(9):2315-2323.
13. Apovian CM, et al. Insurance coverage and prior authorization requirements for anti-obesity medications. Obesity. 2024;32(3):445-454.
14. Fitch A, et al. State obesity treatment mandates and medication access. Obesity Science & Practice. 2024;10(2):e634.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.